Loading stock…

Vir Biotechnology, Inc. (VIR) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Vir Biotechnology, Inc.

VIRMarket cap $1.95BPrice $11.5

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops antibody-based therapies targeting infectious diseases and cancer, engineering the immune system to fight what it normally can't see. Its pipeline tackles hepatitis, HIV, and flu — diseases that have outsmarted vaccines and treatments for decades.

In Bastion Portfolios?

52W Return+99%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-65%1

Revenue Forecast

Rev CAGR (1y)+256%10

Rev CAGR (3y)+15%8

Rev CAGR (5y)+30%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-92%1

Net Income Margin-83%1

Free Cash Flow Margin-67%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-26%1

ROA-21%1

Earnings Stabilityna–

GEAR+VERY WEAK9

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV2.07

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-10.4%1

Dividend Yieldna–

Momentum

Short term

1 month return+3%9

3 month return+10%9

YTD return+91%10

Mid term

Price vs 52wHigh96%10

1 year return+90%10

Long term

3 year return+30%4

5 year return-69%1

Risk Shield

Price Risk

Beta0.76

Volatility64%2

Free Cash Flow

Free Cash Flow Margin-67%1

Free Cash Flow Yield-10.4%1

Quality

ROCE-25%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

VIRVir Biotechnology

Revenue FY25$69M

GROWTH RATING↗

STRONG69 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-65%1

Revenue, next 1Y+256%10

Revenue, next 3Y, CAGR+15%8

Revenue, next 5Y, CAGR+30%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 69% of companies worldwide.

Revenue is set to grow 15%/yr over the next 3 years, ahead of most of the market.9/10

After shrinking over the last 3 years, revenue is set to grow 15%/yr from here.

The runway holds up: revenue is set to grow 30%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Revenue fell 65%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG79 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+3%9

3-month return+10%9

YTD return+91%10

MID & LONG-TERM▾SCORE

% of 52-week high96%10

1-year return+90%10

3-year return+30%4

5-year return-69%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 90% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+3%), over three months (+10%) and so far this year (+91%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+30% over three years and -69% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Vir Biotechnology, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

VIRVir Biotechnology

Revenue FY25$69M

GROWTH RATING↗

STRONG69 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-65%1

Revenue, next 1Y+256%10

Revenue, next 3Y, CAGR+15%8

Revenue, next 5Y, CAGR+30%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 69% of companies worldwide.

Revenue is set to grow 15%/yr over the next 3 years, ahead of most of the market.9/10

After shrinking over the last 3 years, revenue is set to grow 15%/yr from here.

The runway holds up: revenue is set to grow 30%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Revenue fell 65%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG79 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+3%9

3-month return+10%9

YTD return+91%10

MID & LONG-TERM▾SCORE

% of 52-week high96%10

1-year return+90%10

3-year return+30%4

5-year return-69%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 90% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+3%), over three months (+10%) and so far this year (+91%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+30% over three years and -69% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Vir Biotechnology, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community